DISCLAIMER: This website is operated by PricewaterhouseCoopers LLP (“PwC”) on behalf of PricewaterhouseCoopers Public Sector LLP, which was acquired by Veritas Capital on May 1, 2018 and is no longer affiliated with PwC. PwC has no responsibility for the accuracy or availability of the content or information provided on this website. Nothing herein constitutes an endorsement by PwC of the content, products, advertising or other materials presented on this website. PWC DOES NOT MAKE ANY WARRANTIES OR REPRESENTATIONS, EXPRESS OR IMPLIED, REGARDING THE CONTENT OR INFORMATION (INCLUDING THE ACCURACY, QUALITY, RELIABILITY, APPROPRIATENESS OR FITNESS FOR A PARTICULAR PURPOSE THEREOF) PRESENTED ON THIS WEBSITE, AND PWC SHALL HAVE NO LIABILITY OF ANY NATURE WHATSOEVER IN RELATION TO ANY OF THE FOREGOING.
The demand for public healthcare in emerging markets has steadily increased as developing countries transition from poverty-related diseases to chronic, age-related diseases commonplace in more mature markets.
As growth trends in mature markets plateau due to the patent-cliff, rising R&D costs, and more complex, riskier research, global pharmaceutical companies are developing in these areas to explore new sources of profitability in emerging markets.
Government organizations face several challenges around talent development and retention in emerging markets that are compounded by regional and industry-specific talent management complexities. Some of the biggest obstacles:
The following steps offer a methodical and strategic way for public sector organizations to develop their talent strategy: